RenovoRx, Inc.: RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer : vimarsana.com

Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem to Treat Locally

Related Keywords

United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , American , Michael Jon Pishvaian , Shaun Bagai , Gewinn Nur , Michaelj Pishvaian , Jack Perkins , Linkedin , American Association Of Clinical Research , Clinical Research Programsassociate Professor Of Oncology , Company Nasdaq , Strategic Communications , Securities Exchange , Twitter , World Congress On Gastrointestinal Cancer , John Hopkins School Of Public Health , Exchange Commission , Renovorx Inc , R Pac Study , Treat Locally Advanced Pancreatic Cancer , Gastrointestinal Cancer , American Association , Clinical Research , Principal Investigator , Drug Applications , Targeted Intra Arterial Gemcitabine , Locally Advanced Pancreatic Cancer , Developmental Therapeutics , Clinical Research Programsassociate Professor , John Hopkins School , Public Health , Trans Arterial Micro Perfusion , Securities Act , Securities Exchange Act , R Pac Phase , Renovorx , Nnounces , Ate , Reaking , Ral , Resentation , 023 , Smo , Orld , Ongress , Gastrointestinal , Ancer ,